ASCO 2018 | M7824: a promising novel antibody for HPV-associated cancers

James Gulley

In this video, James Gulley, MD, PhD, FACP, of the National Cancer Institute, Bethesda, MD, speaks to us about the development of M7824, a novel antibody capable of targeting PD-L1 and TGF-β simultaneously. Dr Gulley mentions the results obtained from preliminary trials of this drug and the subsequent studies his research group conducted (NCT02517398), all of which generated positive results, and briefly mentions one side effect that, while observed in many patients, was fairly harmless. Dr Gulley then speaks about the differential efficacy observed between HPV positive patients and those with HPV-associated cancers, before concluding his interview with a possible explanation for this. This interview was recorded at the 2018 American Society of Oncology (ASCO) Annual Meeting, held in Chicago, IL.

Share this video